SHARED RESOURCE MANAGEMENT The Lineberger Comprehensive Cancer Center has a strong history of providing high quality and cost-effective shared resources that offer innovative services and technologies to the membership. The oversight of the SRs involves the Director, Deputy Director, and Associate Directors of the Center. Program leaders also provide valuable input and guidance on the services offered. Center members provide feedback through surveys and serve on SR active internal advisory boards for each SR. Over the last five years, this management process has provided substantial new infrastructure for the faculty including: 1) an expanded and more robust tissue- based research pipeline for correlative work, 2) new technologies such as single cell analysis, mass spec cytometer instrumentation, and a CyroEM, 3) expanded faculty SR leadership expertise in pathology and biostatistics. The financial and administrative oversight is provided by the Associate Director of Administration and his staff of 4 FTEs devoted to this endeavor. The SRs are well managed and are well used as demonstrated by these statistics: ? 97% of 2018 user-survey respondents stated the SR overall experience was excellent or good. ? 81% of LCCC Members used a Shared Resource in FY19 ? 82% of FY19 total LCCC managed-Shared Resource users were Center faculty Importantly, the SRs are cost-effective and provide exceptional value to the members. The Center requests 8% of the operating budget for the SRs from the CCSG. This is greatly leveraged through a sustained annual institutional commitment of over $10M in operational support, 37% of the total SR operating budget. The remaining SR operating budget, approximately $14.3M, is recovered by recharge mechanisms. As a result of the CCSG and institutional commitment, members receive discounts on fees, priority access and free consultative services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089825
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Chen, Xiu-Fei; Tian, Meng-Xin; Sun, Ren-Qiang et al. (2018) SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep 19:
Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574

Showing the most recent 10 out of 1525 publications